Stephane Allard, MD, Chief Medical Officer
EpiCept Corp. (Tarrytown, NY)
Dr. Allard was formerly Chief Executive Officer, President, and a
Director of Biovest International. Prior to joining Biovest, Dr.
Allard was Vice President of Medical Affairs of the US affiliate of
Sanofi-Synthelabo, a multi-billion dollar global pharmaceutical
company and was responsible for the medical strategy of products
such as Plavixâ, Ambienâ, Avaproâ, and Eloxatinâ. Dr. Allard served
as President of Synthelabo, Inc. and Director of Research and
Development at Lorex Pharmaceuticals, where he was responsible for
the development of Ambienâ and the start up of Synthelabo, Inc in
the US. He led the clinical activities for products such as Ambienâ,
Kerloneâ and Uroxatralâ and the liaison efforts with the FDA. He
served as European Clinical Director of Clinical Research for
Synthelabo (Paris). Dr. Allard received his medical doctorate from
Rouen Medical College and received a Diplomate of CESAM (Certificate
of Statistical Studies Applied to Medicine) and a PhD in Clinical
Pharmacology and Pharmacokinetics (Pitie Salpetriere Hosp.); Paris,
France.